Goldman Sachs Group Inc Mustang Bio, Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	SELL	$0.35 - $0.72 $3,992 - $8,213	-11,407 Reduced 14.66%	66,412 $24,000
Q1 2023 May 11, 2023	SELL	$0.35 - $0.72 $3,992 - $8,213	-11,407 Reduced 14.66%	66,412 $24,000
Q4 2022 May 14, 2024	SELL	$0.32 - $0.52 $8,925 - $14,504	-27,893 Reduced 26.39%	77,819 $30,000
Q4 2022 Feb 13, 2023	SELL	$0.32 - $0.52 $8,925 - $14,504	-27,893 Reduced 26.39%	77,819 $30,000
Q3 2022 May 14, 2024	SELL	$0.46 - $0.76 $22,091 - $36,499	-48,026 Reduced 31.24%	105,712 $50,000

Q3 2022 Nov 10, 2022	SELL	$0.46 - $0.76 $22,091 - $36,499	-48,026 Reduced 31.24%	105,712 $0
Q2 2022 May 14, 2024	BUY	$0.58 - $1.13 $89,168 - $173,723	153,738 New	153,738 $90,000
Q2 2022 Aug 15, 2022	SELL	$0.58 - $1.13 $19,606 - $38,198	-33,804 Reduced 18.02%	153,738 $90,000
Q1 2022 May 16, 2022	SELL	$0.73 - $1.81 $75,235 - $186,542	-103,062 Reduced 35.46%	187,542 $189,000
Q4 2021 Feb 14, 2022	BUY	$1.66 - $2.64 $69,716 - $110,874	41,998 Added 16.89%	290,604 $483,000
Q3 2021 Nov 10, 2021	BUY	$2.58 - $3.36 $641,403 - $835,316	248,606 New	248,606 $669,000

415K

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $46.3M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.